论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
血清 miR-17-5p 在 2 型糖尿病中的诊断价值及其对慢性并发症的预测价值
Authors Gu P, Yu D, Zhang Y, Chai X
Received 22 May 2025
Accepted for publication 19 August 2025
Published 4 September 2025 Volume 2025:18 Pages 3237—3247
DOI https://doi.org/10.2147/DMSO.S542183
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Rebecca Conway
Ping Gu, Dan Yu, Yu Zhang, Xiaoying Chai
Department of Endocrinology, Affiliated Hospital of Jiangnan University, Wuxi, People’s Republic of China
Correspondence: Xiaoying Chai, Department of Endocrinology, Affiliated Hospital of Jiangnan University, No. 1000 Hefeng Road, Binhu District, Wuxi, Jiangsu, 214000, People’s Republic of China, Email cxy13961786062@163.com
Purpose: This study aims to explore the clinical significance of miR-17-5p in T2DM and its chronic complications.
Patients and Methods: A total of 100 patients with T2DM and 90 healthy controls were included. The expression of miR-17-5p was detected by reverse transcription-polymerase chain reaction. A receiver operating characteristic curve was plotted to evaluate the diagnostic value of miR-17-5p for T2DM. Pearson correlation analysis was used to explore the correlation between miR-17-5p and blood glucose indicators in T2DM patients. The Kaplan-Meier curve and multivariate Cox regression analysis were employed to analyze the factors influencing chronic complications. Liposome-mediated transfection technology was used to transfect miR-17-5p mimics and inhibitors into endothelial progenitor cells (EPCs) respectively, to achieve overexpression and knockdown of miR-17-5p in cells. On this basis, we further investigate the potential molecular mechanism by which miR-17-5p is involved in the occurrence and development of chronic complications inT2DM.
Results: Serum miR-17-5p was significantly downregulated in T2DM patients (vs healthy controls, P< 0.001). The AUC for distinguishing T2DM patients from healthy individuals was 0.932. The expression of this miRNA was significantly negatively correlated with FBG (r=− 0.718) and HbA1c (r=− 0.695) (P< 0.001). Follow-up showed that low expression of miR-17-5p was closely associated with T2DM chronic complications (complication group vs non-complication group, P< 0.001), with an AUC of 0.866 for distinguishing the presence from the absence of complications. Kaplan-Meier analysis indicated that individuals with low miR-17-5p expression had a higher risk of complications (Log-rank P=0.009). Mechanistically, miR-17-5p targets FBXO48 and affects the functions of EPCs.
Conclusion: The expression of miR-17-5p is reduced in T2DM. It influences the functions of EPCs by targeting FBXO48, and may be involved in the occurrence and development of chronic complications of T2DM.
Keywords: T2DM, chronic complications, miR-17-5p, EPCs